DEFA14A: Unity Biotechnology Issues Preferred Stock to Facilitate Dissolution Vote Amid Nasdaq Delisting

Unity Biotechnology, Inc. has issued a single share of Series A Preferred Stock to its sole director, Craig R. Jalbert, with significant voting power to ensure the passage of its planned dissolution proposal.

Summary

• Unity Biotechnology, Inc. (UNBX) entered into a Purchase Agreement on July 22, 2025, to sell one share of newly designated Series A Preferred Stock to Craig R. Jalbert, the Company's President, Secretary, and sole director, for $1.00.
• The Series A Preferred Share carries 600,000,000 votes, but its votes on any Dissolution Proposal must be cast in the same proportion as votes cast by common stockholders, effectively neutralizing the impact of abstentions and broker non-votes.
• The Company's Board of Directors previously approved a Plan of Dissolution on June 27, 2025, and intends to seek stockholder approval for this Dissolution Proposal at a special meeting.
• The Company's common stock was suspended from trading on The Nasdaq Stock Market LLC on July 9, 2025, and now trades on the OTC Pink Marketplace under the symbol UNBX; a Form 25 will be filed to delist the securities from Section 12(b) registration.
• The Series A Preferred Share is not convertible, has a $0.01 dividend preference, is not entitled to liquidation distributions, and automatically transfers back to the Company for no consideration upon stockholder approval of the Dissolution Proposal.

Sentiment

Score: 2

Explanation: The filing indicates the company is undergoing dissolution and has been delisted from Nasdaq, which are highly negative events for shareholders. The preferred stock issuance is a procedural step to facilitate this negative outcome.

Positives

• The issuance of Series A Preferred Stock aims to streamline the stockholder approval process for the Company's planned dissolution, potentially leading to a more efficient wind-down.

Negatives

• The Company's common stock has been suspended from Nasdaq and now trades on the OTC Pink Marketplace, indicating a significant decline in market standing.
• The Board of Directors has approved a Plan of Dissolution, signaling the Company's intent to cease operations and liquidate assets, which is generally a negative outcome for existing shareholders.
• The Series A Preferred Share, despite its high voting power, is not entitled to any distributions upon liquidation, indicating no direct financial benefit for the holder from the dissolution proceeds.

Risks

• The Company may not obtain stockholder approval for the Dissolution Proposal, which could complicate the wind-down process.
• The Company may not realize any value from the sale, license, monetization, or divestiture of its assets and technologies, potentially leaving little or no benefit for creditors and stockholders.
• The Company's ability to complete its planned wind-down and dissolution is subject to various known and unknown risks and uncertainties.

Future Outlook

The Company plans to proceed with its wind-down and dissolution, subject to obtaining stockholder approval for the Dissolution Proposal at a special meeting to be held as soon as reasonably practicable. If approved, a Certificate of Dissolution will be filed. The Company also aims to sell, license, monetize, or divest its assets and technologies to realize potential benefit for its creditors and stockholders.

Management Comments

• The Board of Directors determined that it is in the best interests of the Company and its stockholders that the Company be dissolved.
• The Board approved the Dissolution and seeking stockholder approval of the Dissolution Proposal at a special meeting of stockholders to be held as soon as reasonably practicable.

Industry Context

This announcement reflects a company in the biotechnology sector undergoing a complete wind-down and dissolution. Such events can occur in the highly capital-intensive and research-driven biotech industry due to failed clinical trials, lack of funding, or inability to bring products to market. The delisting from Nasdaq and move to OTC further underscores the Company's distressed state, a common outcome for biotech firms that do not achieve commercial success.

Comparison to Industry Standards

• The delisting from Nasdaq and subsequent trading on the OTC Pink Marketplace is a common trajectory for biotechnology companies that fail to meet listing requirements, often due to low share price, market capitalization, or inability to maintain business operations.
• The decision to dissolve and liquidate assets is a final step for many biotech startups that do not achieve commercial viability, contrasting sharply with successful peers like Amgen or Regeneron, which continue to invest heavily in R&D and expand their product pipelines.
• The mechanism of issuing a high-vote preferred share to a director to facilitate a dissolution vote is an unusual but legally permissible corporate governance maneuver, typically employed to overcome potential hurdles from dispersed common shareholders or activist investors in a wind-down scenario, differing from standard corporate actions seen in healthy, growing companies.

Corporate Governance

Related Party Transactions

• Unity Biotechnology, Inc. sold one share of Series A Preferred Stock to Craig R. Jalbert, the Company's President, Secretary, and sole director, for $1.00.

Stakeholder Impact

• Shareholders: Face the prospect of the Company's dissolution and liquidation, likely resulting in significant or total loss of investment value, especially common stockholders who are not entitled to liquidation distributions from the preferred share structure.
• Creditors: The Company's efforts to monetize assets are intended to realize potential benefit for creditors, indicating a focus on fulfilling obligations before any potential return to shareholders.
• Management (Craig R. Jalbert): Gains significant control over the dissolution vote through the Series A Preferred Share, ensuring the Board's approved plan can proceed.

Next Steps

• The Company will file a proxy statement with the SEC to seek stockholder approval of the Dissolution Proposal.
• A special meeting of stockholders will be held as soon as reasonably practicable to vote on the Dissolution Proposal.
• If the Dissolution Proposal is approved, the Company intends to file a Certificate of Dissolution with the Secretary of State of the State of Delaware.
• The Company plans to file a Form 25 with the SEC to delist its common stock and remove it from registration under Section 12(b) of the Exchange Act.
• The Company will attempt to sell, license, monetize, and/or divest one or more of its assets and technologies.

Key Dates

Recommendation

The filing explicitly states the Company's Board has approved a plan for dissolution and liquidation, and the common stock has already been delisted from Nasdaq, now trading on the OTC Pink. These are definitive indicators of a company ceasing operations and winding down, which typically results in a near-total loss for common shareholders. The issuance of preferred stock is merely a procedural step to facilitate this negative outcome, not to improve the company's prospects. Investors should exit their positions to minimize further losses.

Keywords

Dissolution, Preferred Stock, Corporate Governance, Delisting, SEC Filing, Biotechnology, Liquidation, Shareholder Vote, OTC Pink Marketplace, Wind-down